Ian N Bruce Lupusdoc
8 years ago
#ACR18 @RheumNow abs 2836 maybe it's time to think across connective tissue diseases as well as within them to better understand their molecular taxonomy. A bit of shameless self-promotion!! @Dr_JohnR @tracyannbriggs https://t.co/CL6vH0zbDj
Like most rheumatologists, I retain a deep and abiding love for methotrexate. And with each passing decade since the drug’s ‘re-discovery’ by rheumatology, evidence for a positive trade-off between its benefits and harms has continued to accrue, ensuring its role as the centrepiece of our treatment strategies for rheumatoid arthritis, even as an avalanche of biologics and targeted synthetic DMARDs has swept over us.
There are many avenues for interdisciplinary collaboration within rheumatology, as our specialty encompasses every organ system and diseases with protean manifestations. The intersection of rheumatology and immunology is well known and has become increasingly important, given the association of autoimmune conditions with many of the primary immunodeficiency syndromes.
Nicole Bitencourt NicoleBitencou5
8 years ago
CPT II carnitine palmitoyltransferase 2 defect presents with #recurrent #rhabdomyolisis with exertion. Send plasma acylcarnitine profile in acute phase. #GeneticMimicsOfRheumaticDisease #ACR18 @RheumNow
Arthur Lau ArthurRheum
8 years ago
Enbrel non medical switch study w 89 pts switching. No sig change in DAS28-ESR, SJC/TJC/global scores but only 3 month f/u... data on Enbrel non med switches have been very sparse so every study, even small is important right now @RheumNow #ACR18 https://t.co/DouMLWlIix
Arthur Lau ArthurRheum
8 years ago
Patients and HCPs main concerns re: biosimilars are less efficacy and being forced to switch @RheumNow #ACR18 https://t.co/wDBpxzpPE5
ǝlʇʇıɥʍ ɯɐs samwhittle
8 years ago
#ACR18 Neil Basu from Aberdeen showing some lovely functional brain imaging data that implies that #fibromyalgia symptoms in RA have similar neurobiological signature to ‘primary’ FM. Strong correlation between FM survey score and DMN-insula connectivity.
@RheumNow https://t.co/onrbeLhOYM
Arthur Lau ArthurRheum
8 years ago
Based on this survey, most MDs don’t agree with biosimilar interchangeability, but most pharmacist think it’s ok @RheumNow #ACR18 https://t.co/ZhM2h3AD2b
Ian N Bruce Lupusdoc
8 years ago
#ACR18 @rheumnow abs 2419. In a busy clinic, ask 'one key question' as a way to opening discussion on pregnancy planning in SLE. With an EPR it can even come up as a prompt on your screen. https://t.co/hQwlcxIZrB
Ian N Bruce Lupusdoc
8 years ago
#ACR18 @RheumNow abs 2653. Worryingly over 50% of SLE patients on potentially teratogenic drugs are using less reliable forms of contraception: 6% on nothing. A global issue in SLE. https://t.co/UH2IqaOa8D
Philip Gardiner PhilipGardiner
8 years ago
Abst 1910 Dr Ford followed 340 ACPA+ but no clinical RA pts. Risk of developing future RA depends on titre: 50% of 'hi' ACPA patients develop RA by 5 years of follow-up. #RA #ACR18 @RheumNow
Dr. Arthur Lau: SELECT-COMPARE Trial
Dr. Arthur Lau discusses the SELECT-COMPARE trial as presented at the ACR/ARHP Annual Meeting in Chicago.
Audio Highlights and Interviews from Day 2 at the ACR 2018 meeting - LISTEN HERE
Monday was a packed day of sessions and studies. Here are our just a few of our highlights.
Drs. Jack Cush, Arthur Kavanaugh and Jeffrey Sparks: What's Hot in RA
Drs. Jack Cush, Arthur Kavanaugh and Jeffrey Sparks discuss studies on JAK, drug safety signals, disease activity, RF negative v. positive and other hot RA abstracts being presented at the ACR/ARHP Annual Meeting in Chicago.
